|
Dr. Li is President and Chief Executive Officer, Boston Biomedical, Inc. He is also an adjunct faculty member at Beth Israel Deaconess Medical Center, Harvard Medical School. From September 2003 to January 2007, Dr. Li was Chief Scientific Officer, Executive Vice President and Head of ArQule Biomedical Institute, ArQule Inc (Nasdaq:ARQL). He is the Chairman of ArQule’s scientific advisory board. Dr. Li joined ArQule in September 2003. He previously served as the scientific founder and Vice President of Research at Cyclis Pharmaceuticals, Inc., an Ampersand Ventures portfolio company. Dr. Li was a faculty member of Harvard Medical School, a physician and the Head of a GI Cancer Laboratory at the Beth Israel Deaconess Medical Center, Harvard Medical School. His research team at Harvard invented transkingdom RNAi technology, which promises to accelerate biomedical research and medical therapies based on RNA interference. He is a recipient of a number of awards and recognitions, and has published numerous highly cited articles in top leading science journals. Dr. Li graduated from the Harvard-MIT Division of Health Science and Technology and received his M.D. degree Magna Cum Laude from Harvard Medical School, completed medical residency and fellowship at Harvard’s Brigham Women’s Hospital/Dana-Farber Cancer Institute and Beth Israel Deaconess Medical center, and is a diplomate of the American Board of Internal Medicine. | 